Fig. 4: Ponatinib inhibits different BRAF species and ERK signaling in cells.

a Melanoma A375, SKMEL239-C4, SKMEL-30, SKMEL-2, and lung cancer CALU6 cell lines expressing BRAF^V600E or RAS^MUT/BRAF^WT left untreated or treated with increasing concentration of Ponatinib or Vemurafenib for 1 h, then assayed for western blot and immunoblot with the indicated antibodies to probe ERK-signaling inhibition. Data are representative of three independent experiments. b Breast cancer SKBR3 cells, which are RTK-dependent HER2 amplified and melanoma A375 (BRAF^V600E monomer) cells were left untreated or treated with increasing concentration of Ponatinib and Lapatinib, an EGFR/HER2 inhibitor, for 1 h, then assayed by immunoblot with the indicated antibodies. Data are representative of n = 3 independent experiments. Source data are provided as a Source Data file.